Authors:
SVENSSON J
OHLSSON C
JANSSON JO
MURPHY G
WYSS D
KRUPA D
CERCHIO K
POLVINO W
GERTZ B
BAYLINK D
MOHAN S
BENGTSSON BA
Citation: J. Svensson et al., TREATMENT WITH THE ORAL GROWTH-HORMONE SECRETAGOGUE MK-677 INCREASES MARKERS OF BONE-FORMATION AND BONE-RESORPTION IN OBESE YOUNG MALES, Journal of bone and mineral research, 13(7), 1998, pp. 1158-1166
Citation: R. Dixon et al., FLUOXETINE HAS NO EFFECTS ON THE PHARMACOKINETICS, PHARMACODYNAMICS OR SAFETY PROFILE OF ZOLMITRIPTAN (ZOMIG(TM)), Neurology, 50(4), 1998, pp. 5004-5004
Authors:
SVENSSON J
LONN L
JANSSON JO
MURPHY G
WYSS D
KRUPA D
CERCHIO K
POLVINO W
GERTZ B
BOSEAUS I
SJOSTROM L
BENGTSSON BA
Citation: J. Svensson et al., 2-MONTH TREATMENT OF OBESE SUBJECTS WITH THE ORAL GROWTH-HORMONE (GH)SECRETAGOGUE MK-677 INCREASES GH SECRETION, FAT-FREE MASS, AND ENERGY-EXPENDITURE, The Journal of clinical endocrinology and metabolism, 83(2), 1998, pp. 362-369
Authors:
FRANC JE
KOLLIA G
KATES RE
POLVINO W
SALAZAR DE
Citation: Je. Franc et al., AVITRIPTAN COADMINISTRATION DELAYS ACETAMINOPHEN ABSORPTION BUT DOES NOT ALTER ITS METABOLISM, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 22-22
Authors:
POLVINO W
SCIBERRAS D
GERTZ B
CHENG H
STEPANAVAGE M
WITTREICH J
OLAH T
EDWARDS M
MANT T
Citation: W. Polvino et al., MK-462 - 1ST HUMAN-EXPERIENCE WITH A NOVEL 5-HT1D AGONIST, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 129-129